BioNTech SE is a German biotechnology company that specializes in developing and manufacturing immunotherapies for cancer and other diseases. It was founded in 2008 and is headquartered in Mainz, Germany. BioNTech's most notable achievement is its development of the Pfizer-BioNTech COVID-19 vaccine, which was the first COVID-19 vaccine authorized for emergency use in the United States. The company's immunotherapies are designed to harness the body's immune system to fight cancer and other diseases, and include individualized mRNA-based treatments, as well as cell-based therapies. BioNTech has partnerships with a number of pharmaceutical companies, including Pfizer, Genmab, Sanofi, and Regeneron.
BioNTech SE is a German biotechnology company that specializes in developing and manufacturing immunotherapies for cancer and other diseases. It was founded in 2008 and is headquartered in Mainz, Germany. BioNTech's most notable achievement is its development of the Pfizer-BioNTech COVID-19 vaccine, which was the first COVID-19 vaccine authorized for emergency use in the United States. The company's immunotherapies are designed to harness the body's immune system to fight cancer and other diseases, and include individualized mRNA-based treatments, as well as cell-based therapies. BioNTech has partnerships with a number of pharmaceutical companies, including Pfizer, Genmab, Sanofi, and Regeneron.